METex14 NSCLC responds to the treatment of MET tyrosine kinase inhibitors (MET-TKIs), with the reported objective response rate (ORR) ranging from 32% to 67.9% and median progression-free survival (mPFS) was from 5.4–9.7 months5–8. Here, MET is linked to non-small cell lung carcinoma.